---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-090059"
form_type: "8-K"
ticker: null
cik: "0001851194"
company_name: "Ventyx Biosciences, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:48:51.719270+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Eli Lilly completes acquisition of Ventyx Biosciences for $1.2B; $14.00 per share cash

## Summary
- Merger closed March 4, 2026; Ventyx becomes wholly owned subsidiary of Eli Lilly.
- Common stock converted to $14.00/share; preferred stock to $1,400/share; aggregate ~$1.2B.
- All prior directors and officers resigned; replaced by Eli Lilly appointees.
- Common stock delisted from Nasdaq; Form 25 filed; deregistration planned.
- Equity awards (options, RSUs) cancelled; holders receive cash based on $14.00/share.

## SEC filing metadata
- accession: 0001193125-26-090059
- form_type: 8-K
- cik: 0001851194
- company_name: Ventyx Biosciences, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851194/000119312526090059/0001193125-26-090059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851194/000119312526090059/d116049d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-090059
- JSON: https://secwatch.observer/filing/0001193125-26-090059.json
- Plain text: https://secwatch.observer/filing/0001193125-26-090059.txt

## Source-grounded claims
- claim_id: 39975b4d5b2231d80434db588d43242094454351
  claim: Ventyx Biosciences, Inc.: Amended and restated certificate of incorporation effective at the Effective Time of the Merger.
  evidence_excerpt: the certificate of incorporation and bylaws of the Company were amended and restated in accordance with the terms of the Merger Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851194/000119312526090059/0001193125-26-090059-index.htm
- claim_id: 4ba3f095c3ec4f6bed6a91b4ff1c42d884779b24
  claim: Ventyx Biosciences, Inc.: Amended and restated bylaws effective at the Effective Time of the Merger.
  evidence_excerpt: the certificate of incorporation and bylaws of the Company were amended and restated in accordance with the terms of the Merger Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851194/000119312526090059/0001193125-26-090059-index.htm
- claim_id: 9c1a56780a3b0a9e39655772f9c20cd8fc34b5be
  claim: Ventyx Biosciences, Inc. underwent a change of control involving Eli Lilly and Company for $14.00 per share (closed 2026-03-04).
  evidence_excerpt: (Exact name of Registrant as Specified in Its Charter) Delaware 001-40928 83-2996852 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Eli Lilly and Company Global Headquarters Lilly Corporate Center Indianapolis , Indiana 46285 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: 760 407-6511 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
  evidence_url: https://www.sec.gov/Archives/edgar/data/1851194/000119312526090059/0001193125-26-090059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.